Melatonin for the prevention and treatment of cancer

Oncotarget

Volumn 8, Issue 24, 2017, Pages 39896-39921

  Li, Ya ^a   Li, Sha ^b   Zhou, Yue ^a   Meng, Xiao ^a   Zhang, Jiao Jiao ^a   Xu, Dong Ping ^a   Li, Hua Bin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticancer; Apoptosis; Mechanisms of action; Melatonin; Receptor

Indexed keywords

MELATONIN; MELATONIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENDOMETRIUM CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MOUTH CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; STOMACH CANCER; UTERINE CERVIX CANCER; ANIMAL; METABOLISM; NEOPLASM;

ANIMALS; HUMANS; MELATONIN; NEOPLASMS; RECEPTORS, MELATONIN;

EID: 85020689840     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16379     Document Type: Article

References (199)

1. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med. 2009; 11:e5
2. Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, Rosales-Corral S, Tan D, Reiter RJ. Extrapineal melatonin: Sources, regulation, and potential functions. Cell Mol Life Sci. 2014; 71:2997-3025
3. Ekmekcioglu C. Melatonin receptors in humans: Biological role and clinical relevance. Biomed Pharmacother. 2006; 60:97-108
4. Li AN, Xu XR, Li S, Guo YJ, Liu JL, Li HB. Secretion and bioactivity of melatonin. Int J Mod Biol Med. 2012; 1:21-39
5. Stehle JH, Saade A, Rawashdeh O, Ackermann K, Jilg A, Sebestény T, Maronde E. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res. 2011; 51:17-43
6. Reiter RJ. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991; 12:151-180
7. Stehle JH, Von Gall C, Korf HW. Melatonin: A clockoutput, a clock-input. 2003; 15:383-389
8. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol. 2012; 351:152-166
9. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 2014; 64:207-218
10. WHO. 2015. Available online: http://www.who.int/mediacentre/factsheets/fs297/en/(accessed on 17 September 2016)
11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7-30
12. Zhang JJ, Li Y, Zhou T, Xu DP, Zhang P, Li S, Li HB. Bioactivities and health benefits of mushrooms mainly from China. Molecules. 2016; 21:938
13. Li Y, Zhang JJ, Xu DP, Zhou T, Zhou Y, Li S, Li HB. Bioactivities and health benefits of wild fruits. Int J Mol Sci. 2016; 17:1258
14. Zhou Y, Zheng J, Li Y, Xu DP, Li S, Chen YM, Li HB. Natural polyphenols for prevention and treatment of cancer. Nutrients. 2016; 8:515
15. Zheng J, Zhou Y, Li Y, Xu DP, Li S, Li HB. Spices for prevention and treatment of cancers. Nutrients. 2016; 8:495
16. Xu DP, Zheng J, Zhou Y, Li Y, Li S, Li HB. Extraction of natural antioxidants from the Thelephora ganbajun mushroom by an ultrasound-assisted extraction technique and evaluation of antiproliferative activity of the extract against human cancer cells. Int J Mol Sci. 2016; 17:1664
17. Zhang YJ, Gan RY, Li S, Zhou Y, Li AN, Xu DP, Li HB. Antioxidant phytochemicals for the prevention and treatment of chronic diseases. Molecules. 2015; 20:21138-21156
18. Li AN, Li S, Zhang YJ, Xu XR, Chen YM, Li HB. Resources and biological activities of natural polyphenols. Nutrients. 2014; 6:6020-6047
19. Li F, Li S, Li HB, Deng GF, Ling WH, Wu S, Xu XR, Chen F. Antiproliferative activity of peels, pulps and seeds of 61 fruits. J Funct Foods. 2013; 5:1298-1309
20. Li F, Li S, Li HB, Deng GF, Ling WH, Xu XR. Antiproliferative activities of tea and herbal infusions. Food Funct. 2013; 4:530-538
21. Xia EQ, Deng GF, Guo YJ, Li HB. Biological activities of polyphenols from grapes. Int J Mol Sci. 2010; 11:622-646
22. Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S, Galli F. Melatonin signaling and cell protection function. Faseb J. 2010; 24:3603-3624
23. Vijayalaxmi, Thomas CR, Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol. 2002; 20:2575-2601
24. Cutando A, Lopez-Valverde A, Arias-Santiago S, De Vicente J, De Diego RG. Role of melatonin in cancer treatment. Anticancer Res. 2012; 32:2747-2753
25. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: Possible mechanisms. Integr Cancer Ther. 2008; 7:189-203
26. Reppert SM. Melatonin receptors: Molecular biology of a new family of G protein-coupled receptors. J Biol Rhythm. 1997; 12:528-531
27. Deming SL, Lu W, Beeghly-Fadiel A, Zheng Y, Cai QY, Long JR, Shu XO, Gao YT, Zheng W. Melatonin pathway genes and breast cancer risk among Chinese women. Breast Cancer Res Tr. 2012; 132:693-699
28. Jung B, Ahmad N. Melatonin in cancer management: Progress and promise. Cancer Res. 2006; 66:9789-9793
29. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: Differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003; 60:1407-1426
30. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, Hauch A, Lundberg PW, Summers W, Yuan L, Frasch T, Blask DE. Melatonin: An inhibitor of breast cancer. Endocr Relat Cancer. 2015; 22:R183-R204
31. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ. Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Inv Drug. 2012; 21:819-831
32. Yang WS, Deng Q, Fan WY, Wang WY, Wang X. Light exposure at night, sleep duration, melatonin, and breast cancer: A dose-response analysis of observational studies. Eur J Cancer Prev. 2014; 23:269-276
33. Abd El Moneim NA, El Masry H, Sorial MM. A molecular case-control study on the association of melatonin hormone and rs#10830963 single nucleotide polymorphism in its receptor MTNR1B gene with breast cancer. Middle East J cancer. 2015; 6:11-20
34. Basler M, Jetter A, Fink D, Seifert B, Kullak-Ublick GA, Trojan A. Urinary excretion of melatonin and association with breast cancer: Meta-Analysis and review of the literature. Breast Care. 2014; 9:182-187
35. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the nurses' health study cohort. Cancer Epidem Biomar. 2009; 18:74-79
36. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: A prospective study. J Natl Cancer Inst. 2004; 96:475-482
37. Sturgeon SR, Doherty A, Reeves KW, Bigelow C, Stanczyk FZ, Ockene JK, Liu S, Manson JE, Neuhouser ML. Urinary levels of melatonin and risk of postmenopausal breast cancer: Women's health initiative observational cohort. Cancer Epidem Biomar. 2014; 23:629-637
38. Brown SB, Hankinson SE, Eliassen AH, Reeves KW, Qian J, Arcaro KF, Wegrzyn LR, Willett WC, Schernhammer ES. Urinary melatonin concentration and the risk of breast cancer in nurses' health study II. Am J Epidemiol. 2015; 181:155-162
39. Wang XS, Tipper S, Appleby PN, Allen NE, Key TJ, Travis RC. First-Morning urinary melatonin and breast cancer risk in the guernsey study. Am J Epidemiol. 2014; 179:584-593
40. Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund T, Stampfer MJ, et al. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2015; 67:191-194
41. Tai S, Huang S, Bao B, Wu M. Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A casecontrol study. Sci Rep. 2016; 6:29606
42. Zhao M, Wan JY, Zeng K, Tong M, Lee AC, Ding JX, Chen Q. The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: A retrospective study. J Cancer. 2016; 7:831-836
43. Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ, Dong TF, Fu QL. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A metaanalysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012; 69:1213-1220
44. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely A, Mills E. Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012; 11:293-303
45. Poole EM, Schernhammer E, Mills L, Hankinson SE, Tworoger SS. Urinary melatonin and risk of ovarian cancer. Cancer Causes Control. 2015; 26:1501-1506
46. Parkin DM. International variation. Oncogene. 2004; 23:6329-6340
47. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21 WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999; 65:415-420
48. Aubert C, Janiaud P, Lecalvez J. Effect of pinealectomy and melatonin on mammary tumor growth in SpragueeDawley rats under different conditions of lighting. J. Neural Transm. 1980; 47:121-130
49. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 1981; 41:4432-4436
50. Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuno D, Sanchez-Barcelo EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res. 2002; 32:90-96
51. Girgert R, Bartsch C, Hill SM, Kreienberg R, Hanf V. Tracking, the elusive antiestrogenic effect of melatonin: A new methodological approach. Neuroendocrinol Lett. 2003; 24:440-444
52. Martinez-Campa C, Alonso-Gonzalez C, Mediavilla MD, Cos S, Gonzalez A, Ramos S, Sanchez-Barcelo EJ. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res. 2006; 40:291-296
53. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 2005; 38:136-142
54. Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett. 2003; 189:49-57
55. Lai L, Yuan L, Cheng Q, Dong CM, Mao LL, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat. 2009; 118:293-305
56. Jardim-Perassi BV, Lourenco MR, Doho GM, Grigolo IH, Gelaleti GB, Ferreira LC, Borin TF, Moschetta MG, Zuccari D. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anticancer Agents Med Chem. 2016; 16:347-358
57. Goncalves ND, Colombo J, Lopes JR, Gelaleti GB, Moschetta MG, Sonehara NM, Hellmen E, Zanon CD, Oliani SM, Zuccari D. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. PloS One. 2016; 11:e0150407
58. Mao LL, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010; 12:R107
59. Lopes JR, Maschio LB, Jardim-Perassi BV, Moschetta MG, Ferreira LC, Martins GR, Gelaleti GB, Zuccari D. Evaluation of melatonin treatment in primary culture of canine mammary tumors. Oncol Rep. 2015; 33:311-319
60. Wang JS, Xiao XS, Zhang Y, Shi DB, Chen WB, Fu LY, Liu LQ, Xie FY, Kang TB, Huang WL, Deng WG. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res. 2012; 53:77-90
61. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni G. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett. 2001; 22:45-47
62. Alvarez-Garcia V, Gonzalez A, Alonso-Gonzalez C, Martinez-Campa C, Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res. 2013; 54:373-380
63. Zuccari D, Jardim BV, Lopes JR, Borin TF, Gelaleti GB, Moschetta MG, Leonel C, Ferreira LC, Maschio LB, Goncalves NN. Evaluation of hypoxia inducible factor 1-Alpha (HIF1) after treatment with melatonin in breast cancer cell line. Eur J Cancer. 2012; 485:S254-S255
64. Chottanapund S, Van Duursen M, Navasumrit P, Hunsonti P, Timtavorn S, Ruchirawat M, Van den Berg M. Antiaromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts. Toxicol in Vitro. 2014; 28:1215-1221
65. Martinez-Campa C, Gonzalez A, Mediavilla MD, Alonso-Gonzalez C, Alvarez-Garcia V, Sanchez-Barcelo EJ, Cos S. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer. 2009; 101:1613-1619
66. Knower KC, To SQ, Takagi K, Miki Y, Sasano H, Simpson ER, Clyne CD. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat. 2012; 132:765-771
67. Alvarez-Garcia V, Gonzalez A, Alonso-Gonzalez C, Martinez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res. 2012; 52:282-290
68. Lee SE, Kim SJ, Yang H, Jeong SI, Hwang SY, Park CS, Park YS. Molecular analysis of melatonin-induced changes in breast cancer cells: Microarray study of anti-cancer effect of melatonin. Biochip J. 2011; 5:353-361
69. Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS, Park YS. MicroRNA and gene expression analysis of melatoninexposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res. 2011; 51:345-352
70. Lee SE, Kim SJ, Yoon HJ, Yu SY, Yang H, Il Jeong S, Hwang SY, Park CS, Park YS. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. J Pineal Res. 2013; 54:80-88
71. Mori F, Ferraiuolo M, Santoro R, Sacconi A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P, Blandino G, Strano S. Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget. 2016; 7:20532-20548. doi: 10.18632/oncotarget.7978
72. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002; 192:147-156
73. Mao LL, Yuan L, Xiang SL, Zeringue SB, Dauchy RT, Blask DE, Hauch A, Hill SM. Molecular deficiency (ies) in MT1 melatonin signaling pathway underlies the melatoninunresponsive phenotype in MDA-MB-231 human breast cancer cells. J Pineal Res. 2014; 56:246-253
74. Kosar PA, Naziroglu M, Ovey IS, Cig B. Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: Involvement of TRPV1 channels. J Membrane Biol. 2016; 249:129-140
75. Yun SM, Woo SH, Oh ST, Hong SE, Choe TB, Ye SK, Kim EK, Seong MK, Kim HA, Noh WC, Lee JK, Jin HO, Lee YH, et al. Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. Mol Cell Endocrinol. 2016; 422:64-73
76. Jung JH, Sohn EJ, Shin EA, Lee D, Kim B, Jung DB, Kim JH, Yun M, Lee HJ, Park YK, Kim SH. Melatonin suppresses the expression of 45S preribosomal RNA and upstream binding factor and enhances the antitumor activity of puromycin in MDA-MB-231 breast cancer cells. Evid Based Complement Alternat Med. 2013; 2013:879746
77. Margheri M, Pacini N, Tani A, Nosi D, Squecco R, Dama A, Masala E, Francini F, Zecchi-Orlandini S, Formigli L. Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: Molecular basis for the anticancer effect of these molecules. Eur J Pharmacol. 2012; 681:34-43
78. Proietti S, Cucina A, D'Anselmi F, Dinicola S, Pasqualato A, Lisi E, Bizzarri M. Melatonin and vitamin D-3 synergistically down-regulate Akt and MDM2 leading to TGF-1-dependent growth inhibition of breast cancer cells. J Pineal Res. 2011; 50:150-158
79. Alonso-Gonzalez C, Gonzalez A, Martinez-Campa C, Gomez-Arozamena J, Cos S. Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. J Pineal Res. 2015; 58:189-197
80. Alonso-Gonzalez C, Gonzalez A, Martinez-Campa C, Menendez-Menendez J, Gomez-Arozamena J, Garcia-Vidal A, Cos S. Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis. Cancer Lett. 2016; 370:145-152
81. Borin TF, Arbab AS, Gelaleti GB, Ferreira LC, Moschetta MG, Jardim-Perassi BV, Iskander A, Varma N, Shankar A, Coimbra VB, Fabri VA, de Oliveira JG, Zuccari D. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. J Pineal Res. 2016; 60:3-15
82. Jardim-Perassi BV, Arbab AS, Ferreira LC, Borin TF, Varma N, Iskander A, Shankar A, Ali MM, Zuccari D. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PloS One. 2014; 9:e853111
83. Schwimmer H, Metzer A, Pilosof Y, Szyf M, Machnes ZM, Fares F, Harel O, Haim A. Light at night and melatonin have opposite effects on breast cancer tumors in mice assessed by growth rates and global DNA methylation. Chronobiol Int. 2014; 31:144-150
84. Mao LL, Dauchy RT, Blask DE, Slakey LM, Xiang SL, Yuan L, Dauchy EM, Shan B, Brainard GC, Hanifin JP, Frasch T, Duplessis TT, Hill SM. Circadian gating of Epithelial-to-Mesenchymal transition in breast cancer cells via Melatonin-Regulation of GSK3. Mol Endocrinol. 2012; 26:1808-1820
85. Kassayova M, Bobrov N, Strojny L, Orendas P, Demeckova V, Jendzelovsky R, Kubatka P, Kiskova T, Kruzliak P, Adamkov M, Bomba A, Fedorocko P. Anticancer and immunomodulatory effects of lactobacillus plantarum LS/07, inulin and melatonin in NMU-induced rat model of breast cancer. Anticancer Res. 2016; 36:2719-2728
86. Talib WH, Saleh S. Propionibacterium acnes augments antitumor, anti-angiogenesis and immunomodulatory effects of melatonin on breast cancer implanted in mice. PloS One. 2015; 10:e01243844
87. Ma C, Li LX, Zhang Y, Xiang C, Ma T, Ma ZQ, Zhang ZP. Protective and sensitive effects of melatonin combined with adriamycin on ER plus (estrogen receptor) breast cancer. Eur J Gynaecol Oncol. 2015; 36:197-202
88. Orendas P, Kubatka P, Bojkova B, Kassayova M, Kajo K, Vybohova D, Kruzliak P, Pec M, Adamkov M, Kapinova A, Adamicova K, Sadlonova V, Chmelova M, et al. Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model. Int J Exp Pathol. 2014; 95:401-410
89. Xiang SL, Dauchy RT, Hauch A, Mao LL, Yuan L, Wren MA, Belancio VP, Mondal D, Frasch T, Blask DE, Hill SM. Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. J Pineal Res. 2015; 59:60-69
90. Dauchy RT, Xiang SL, Mao LL, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG, Blask DE, Hill SM. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res. 2014; 74:4099-4110
91. Wong MCS, Goggins WB, Wang HHX, Fung FDH, Leung C, Wong SYS, Ng CF, Sung JJY. Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016; 70:862-874
92. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005; 63:29-43
93. Sohn EJ, Won G, Lee J, Lee S, Kim SH. Upregulation of miRNA3195 and miRNA374b mediates the Anti-Angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. J Cancer. 2015; 6:19-28
94. Tam CW, Shiu S. Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: Potential implications for therapeutic strategies against prostate cancer. J Pineal Res. 2011; 51:297-312
95. Shiu S, Leung WY, Tam CW, Liu V, Yao KM. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-B): Potential implications on prostate cancer chemoprevention and therapy. J Pineal Res. 2013; 54:69-79
96. Cho SY, Lee HJ, Jeong SJ, Lee HJ, Kim HS, Chen CY, Lee EO, Kim SH. Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1 alpha inactivation in hypoxic PC-3 prostate cancer cells. J Pineal Res. 2011; 51:87-93
97. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer: A target for prostate cancer management via its inhibition? J Biol Chem. 2009; 284:3823-3832
98. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2011; 50:140-149
99. Rodriguez-Garcia A, Mayo JC, Hevia D, Quiros-Gonzalez I, Navarro M, Sainz RM. Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J Pineal Res. 2013; 54:33-45
100. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010; 49:60-68
101. Dauchy RT, Hoffman AE, Wren-Dail MA, Hanifin JP, Warfield B, Brainard GC, Xiang S, Yuan L, Hill SM, Belancio VP, Dauchy EM, Smith K, Blask DE. Daytime blue light enhances the nighttime circadian melatonin inhibition of human prostate cancer growth. Comparative Med. 2015; 65:473-485
102. Paroni R, Terraneo L, Bonomini F, Finati E, Virgili E, Bianciardi P, Favero G, Fraschini F, Reiter RJ, Rezzani R, Samaja M. Antitumour activity of melatonin in a mouse model of human prostate cancer: Relationship with hypoxia signalling. J Pineal Res. 2014; 57:43-52
103. Dauchy RT, Cecil KS, Dauchy EM, Hanifin JP, Mao LL, Slakey LM, Belancio VP, Hill SM, Brainard GC, Blask DE. Melatonin-depleted blood from healthy adult men exposed to environmental light at night stimulates growth, signal transduction and metabolic activity of tissue-isolated human prostate cancer xenografts in nude rats. Cancer Res. 2011; 71:1324
104. Jablonska K, Pula B, Zemla A, Kobierzycki C, Kedzia W, Nowak-Markwitz E, Spaczynski M, Zabel M, Podhorska-Okolow M, Dziegiel P. Expression of the MT1 melatonin receptor in ovarian cancer cells. Int J Mol Sci. 2014; 15:23074-23089
105. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type i and type II. Biomed Res Int. 2014; 2014:1-11
106. Shen CJ, Chang CC, Chen YT, Lai CS, Hsu YC. Melatonin suppresses the growth of ovarian cancer cell lines (OVCAR-429 and PA-1) and potentiates the effect of g1 arrest by targeting CDKs. Int J Mol Sci. 2016; 17:176
107. Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY, Kim SH. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res. 2012; 52:244-252
108. Chuffa L, Fioruci-Fontanelli BA, Mendes LO, Favaro WJ, Pinheiro P, Martinez M, Martinez FE. Characterization of chemically induced ovarian carcinomas in an Ethanol-Preferring rat model: Influence of Long-Term melatonin treatment. PloS One. 2013; 8:e8167612
109. Chuffa L, Alves MS, Martinez M, Camargo I, Pinheiro P, Domeniconi RF, Junior L, Martinez FE. Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma. Endocr Relat Cancer. 2016; 23:65-76
110. Chuffa L, Fioruci-Fontanelli BA, Mendes LO, Seiva F, Martinez M, Favaro WJ, Domeniconi RF, Pinheiro P, Dos Santos LD, Martinez FE. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88-and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer. 2015; 15:34
111. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Brit J Cancer. 2011; 104:1241-1245
112. Ferreira GM, Martinez M, Camargo I, Domeniconi RF, Martinez FE, Chuffa L. Melatonin attenuates her-2, p38 MAPK, p-AKT, and mTOR levels in ovarian carcinoma of Ethanol-Preferring rats. J Cancer. 2014; 5:728-735
113. Scarinci IC, Garcia FAR, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE. Cervical cancer prevention. Cancer. 2010; 116: 2531-2542
114. Pariente R, Pariente JA, Rodriguez AB, Espino J. Melatonin sensitizes human cervical cancer HeLa cells to cisplatininduced cytotoxicity and apoptosis: Effects on oxidative stress and DNA fragmentation. J Pineal Res. 2016; 60:55-64
115. Dauchy RT, Dauchy EM, Mao LL, Wren MA, Belancio VP, Hill SM, Blask DE. The circadian neurohormone melatonin inhibits aerobic glycolysis (Warburg effect) and fatty acid metabolic signaling in human colorectal and cervical cancer. Cancer Res. 2013; 73:4001
116. Dauchy RT, Dauchy EM, Belancio VP, Mao LL, Hill SM, Sauer LA, Blask DE. Melatonin inhibition of linoleic acid transport and 13-HODE production in HeLa human cervical adenocarcinoma occurs via receptor-mediated signal transduction. Cancer Res. 2012; 72:5167
117. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: Not your grandmother's cancer. Cancer. 2016; 122:2787-2798
118. Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res. 2000; 28:227-233
119. Ciortea R, Costin N, Braicu I, Haragas D, Hudacsko A, Bondor C, Mihu D, Mihu CM. Effect of melatonin on intraabdominal fat in correlation with endometrial proliferation in ovariectomized rats. Anticancer Res. 2011; 31:2637-2643
120. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45:309-316
121. Yeh CM, Lin CW, Yang JS, Yang WE, Su SC, Yang SF. Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation. Oncotarget. 2016; 7:21952-21967 doi: 10.18632/oncotarget.8009
122. Goncalves ND, Rodrigues RV, Jardim-Perassi BV, Moschetta MG, Lopes JR, Colombo J, Zuccari D. Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. Anticancer Agents Med Chem. 2014; 14:1302-1311
123. D'Alessandro LA, Meyer R, Klingmüller U. Hepatocellular carcinoma: A systems biology perspective. Front Physiol. 2013; 4:28
124. Zhou Y, Li Y, Zhou T, Zheng J, Li S, Li H. Dietary natural products for prevention and treatment of liver cancer. Nutrients. 2016; 8:156
125. Kapitanov T, Neumann UP, Schmeding M. Hepatocellular carcinoma in liver cirrhosis: Surgical resection versus transarterial chemoembolization-a Meta-Analysis. Gastroent Res Pract. 2015; 2015:1-8
126. Ordonez R, Carbajo-Pescador S, Prieto-Dominguez N, Garcia-Palomo A, Gonzalez-Gallego J, Mauriz JL. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res. 2014; 56:20-30
127. Carbajo-Pescador S, Ordonez R, Benet M, Jover R, Garcia-Palomo A, Mauriz JL, Gonzalez-Gallego J. Inhibition of VEGF expression through blockade of Hif1 alpha and STAT3 signaling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Brit J Cancer. 2013; 109:83-91
128. Fan LL, Sun GP, Ma T, Zhong F, Wei W. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting Survivin and XIAP. J Pineal Res. 2013; 55:174-183
129. 2 cells. Brit J Cancer. 2013; 108:442-449
130. Carbajo-Pescador S, Garcia-Palomo A, Martin-Renedo J, Piva M, Gonzalez-Gallego J, Mauriz JL. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: Role of the MT1 receptor. J Pineal Res. 2011; 51:463-471
131. Zha LX, Fan LL, Sun GP, Wang H, Ma T, Zhong F, Wei W. Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis. J Pineal Res. 2012; 52:322-331
132. Verma D, Hashim OH, Jayapalan JJ, Subramanian P. Effect of melatonin on antioxidant status and circadian activity rhythm during hepatocarcinogenesis in mice. J Cancer Res Ther. 2014; 10:1040-1044
133. Moreira AJ, Ordonez R, Cerski CT, Picada JN, Garcia-Palomo A, Marroni NP, Mauriz JL, Gonzalez-Gallego J. Melatonin activates endoplasmic reticulum stress and apoptosis in rats with diethylnitrosamine-induced hepatocarcinogenesis. PloS One. 2015; 10:e014451712
134. Compérat E, Camparo P. Histological classification of malignant renal tumours at a time of major diagnostic and therapeutic changes. Diagn Interv Imaging. 2012; 93:221-231
135. Lin Y, Lee L, Lee W, Chu C, Tan P, Yang Y, Chen W, Yang S, Hsiao M, Chien M. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-B DNA-binding activity. J Pineal Res. 2016; 60:277-290
136. Park EJ, Woo SM, Min KJ, Kwon TK. Transcriptional and post-translational regulation of Bim controls apoptosis in melatonin-treated human renal cancer Caki cells. J Pineal Res. 2014; 56:97-106
137. Min KJ, Kim HS, Park EJ, Kwon TK. Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen species-mediated upregulation of CCAAT-enhancerbinding protein homologous protein in human renal cancer cells. J Pineal Res. 2012; 53:99-106
138. Um HJ, Park JW, Kwon TK. Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA. J Pineal Res. 2011; 50:359-366
139. Costa G, Thuler LCS, Ferreira CG. Epidemiological changes in the histological subtypes of 35,018 non-smallcell lung cancer cases in Brazil. Lung Cancer. 2016; 97:66-72
140. Lu JJ, Fu LY, Tang ZP, Zhang CL, Qin LJ, Wang JS, Yu ZL, Shi DB, Xiao XS, Xie FY, Huang WL, Deng WG. Melatonin inhibits AP-2/hTERT, NF-B/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells. Oncotarget. 2016; 7:2985-3001. doi: 10.18632/oncotarget.6407
141. Ma ZQ, Yang Y, Fan CX, Han J, Wang DJ, Di SY, Hu W, Liu D, Li XF, Reiter RJ, Yan XL. Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget. 2016; 7:46768-46784. doi: 10.18632/oncotarget.8776
142. Kim W, Jeong JW, Kim JE. CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells. Tumor Biol. 2014; 35:10919-10929
143. Zhou QY, Gui SY, Zhou Q, Wang Y. Melatonin inhibits the migration of human lung adenocarcinoma a549 cell lines involving JNK/MAPK pathway. PloS One. 2014; 9:e1011327
144. Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J, Kim SH. Melatonin sensitizes h1975 Non-Small-Cell lung cancer cells harboring a T790M-Targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. Cell Physiol Biochem. 2014; 34:865-872
145. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroentero. 2006; 12:354-362
146. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108
147. Wang RX, Liu H, Xu L, Zhang H, Zhou RX. Involvement of nuclear receptor RZR/ROR gamma in melatonin-induced HIF-1 alpha inactivation in SGC-7901 human gastric cancer cells. Oncol Rep. 2015; 34:2541-2546
148. Zhou RX, Wang RX, Song J, Zhang H, Luo JH, Liu H. Melatonin inhibit the angiogenesis of gastric cancer by nuclear receptor. Faseb J. 2015; 291
149. Li WM, Fan MD, Chen YN, Zhao Q, Song CY, Yan Y, Jin Y, Huang ZM, Lin CJ, Wu JS. Melatonin induces cell apoptosis in AGS cells through the activation of JNK and p38 MAPK and the suppression of nuclear Factor-Kappa b: A novel therapeutic implication for gastric cancer. Cell Physiol Biochem. 2015; 37:2323-2338
150. Zhang S, Qi Y, Zhang H, He W, Zhou Q, Gui S, Wang Y. Melatonin inhibits cell growth and migration, but promotes apoptosis in gastric cancer cell line, SGC7901. Biotech Histochem. 2013; 88:281-289
151. Xu L, Liu H, Zhang H, Wang RX, Song J, Zhou RX. Growth-Inhibitory activity of melatonin on murine foregastric carcinoma cells in vitro and the underlying molecular mechanism. Anat Rec. 2013; 296:914-920
152. Liu H, Xu L, Wei JE, Xie MR, Wang SE, Zhou RX. Role of CD4+CD25+ regulatory t cells in Melatonin-Mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. Anat Rec (Hoboken). 2011; 294:781-788
153. Zhang SM, Zuo L, Gui SY, Zhou Q, Wei W, Wang Y. Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Rep. 2012; 39:2843-2849
154. Wu SM, Lin WY, Shen CC, Pan HC, Keh-Bin W, Chen YC, Jan YJ, Lai DW, Tang SC, Tien HR, Chiu CS, Tsai TC, Lai YL, et al. Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated C/EBP and NFB cleavage. J Pineal Res. 2016; 60:142-154
155. Leja-Szpak A, Jaworek J, Pierzchalski P, Reiter RJ. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res. 2010; 49:248-255
156. Sung-Sik Han, Jin-Young Jang, Sun-Whe Kim, Woo-Ho Kim, Kuhn Uk Lee, Yong-Hyun Park. Analysis of longterm survivors after surgical resection for pancreatic cancer. Pancreas. 2006; 32:271-275
157. Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: Potential clinical implications. Med Sci Monitor. 2006; 12:RA186-RA193
158. Lv D, Cui PL, Yao SW, Xu YQ, Yang ZX. Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells. Chinese J Cancer Res. 2012; 24:310-316
159. Gonzalez A, Del Castillo-Vaquero A, Miro-Moran A, Tapia JA, Salido GM. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J Pineal Res. 2011; 50:250-260
160. Xu CF, Wu AR, Zhu H, Fang HY, Xu LL, Ye JX, Shen JQ. Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance. Biomed Pharmacother. 2013; 67:133-139
161. Uguz AC, Cig B, Espino J, Bejarano I, Naziroglu M, Rodriguez AB, Pariente JA. Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res. 2012; 53:91-98
162. Ruiz-Rabelo J, Vazquez R, Arjona A, Perea D, Montilla P, Tunez I, Muntane J, Padillo J. Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. Pancreas. 2011; 40:410-414
163. Lea A, Allingham-Hawkins D, Levine S. BRAF p.Val600Glu (V600E) testing for assessment of treatment options in metastatic colorectal cancer. PLoS Curr. 2010; 2:RRN1187
164. Buldak RJ, Pilc-Gumula K, Buldak L, Witkowska D, Kukla M, Polaniak R, Zwirska-Korczala K. Effects of ghrelin, leptin and melatonin on the levels of reactive oxygen species, antioxidant enzyme activity and viability of the HCT 116 human colorectal carcinoma cell line. Mol Med Rep. 2015; 12:2275-2282
165. Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, Camacho E, Espinosa A, Gallo MA, Acuna-Castroviejo D. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res. 2007; 43:195-205
166. Wei JY, Li WM, Zhou LL, Lu QN, He W. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J Pineal Res. 2015; 58:429-438
167. Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 2013; 13:637-651
168. Leon J, Casado J, Ruiz S, Zurita MS, Gonzalez-Puga C, Rejon JD, Gila A, de Rueda PM, Pavon EJ, Reiter RJ, Ruiz-Extremera A, Salmeron J. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-B. J Pineal Res. 2014; 56:415-426
169. Batista A, Da Silva TG, Teixeira A, de Medeiros PL, Teixeira VW, Alves LC, Dos Santos F, Silva EC. Ultrastructural aspects of melatonin cytotoxicity on Caco-2 cells in vitro. Micron. 2014; 59:17-23
170. Hong Y, Won J, Lee Y, Lee S, Park K, Chang KT, Hong Y. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J Pineal Res. 2014; 56:264-274
171. Nemeth C, Humpeler S, Kallay E, Mesteri I, Svoboda M, Rogelsperger O, Klammer N, Thalhammer T, Ekmekcioglu C. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. J Biol Regul Homeost Agents. 2011; 25:531-542
172. Wang JS, Guo W, Chen WB, Yu WD, Tian Y, Fu LY, Shi DB, Tong B, Xiao XS, Huang WL, Deng WG. Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. J Pineal Res. 2013; 54:406-416
173. Trivedi PP, Jena GB, Tikoo KB, Kumar V. Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Mol Carcinogen. 2016; 55:255-267
174. Anisimov VN, Kvetnoy IM, Chumakova NK, Kvetnaya TV, Molotkov AO, Pogudina NA, Popovich IG, Popuchiev VV, Zabezhinski MA, Bartsch H, Bartsch C. Melatonin and colon carcinogenesis. II. Intestinal melatonincontaining cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors. Exp Toxicol Pathol. 1999; 51:47-52
175. Kannen V, Marini T, Zanette DL, Frajacomo FT, Silva G, Silva WA, Garcia SB. The melatonin action on stromal stem cells within pericryptal area in colon cancer model under constant light. Biochem Bioph Res Co. 2011; 405:593-598
176. Kim HS, Kim TJ, Yoo YM. Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells. PloS One. 2014; 9:e926273
177. Yi CH, Zhang Y, Yu ZL, Xiao Y, Wang JS, Qiu HJ, Yu WD, Tang RR, Yuan YH, Guo W, Deng WG. Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-B/p300 signaling pathways. PloS One. 2014; 9:e999437
178. Bonmati-Carrion MA, Alvarez-Sanchez N, Hardeland R, Madrid JA, Rol MA. A comparison of b16 melanoma cells and 3T3 fibroblasts concerning cell viability and ROS production in the presence of melatonin, tested over a wide range of concentrations. Int J Mol Sci. 2013; 14:3901-3920
179. Wang BQ, Yang QH, Xu RK, Xu JN. Elevated levels of mitochonrial respiratory complexes activities and ATP production in 17-estradiol-induced prolactin-secretory tumor cells in male rats are inhibited by melatonin in vivo and in vitro. Chin Med J (Engl). 2013; 126:4724-4730
180. Mao LL, Dauchy RT, Blask DE, Dauchy EM, Slakey LM, Brimer S, Yuan L, Xiang SL, Hauch A, Smith K, Frasch T, Belancio VP, Wren MA, et al. Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma. J Pineal Res. 2016; 60:167-177
181. Burattini S, Battistelli M, Codenotti S, Falcieri E, Fanzani A, Salucci S. Melatonin action in tumor skeletal muscle cells: An ultrastructural study. Acta Histochem. 2016; 118:278-285
182. Batista APC, Da Silva TG, Teixeira AAC, de Medeiros PL, Teixeira VW, Alves LC, Dos Santos FAB. Melatonin effect on the ultrastructure of Ehrlich ascites tumor cells, lifetime and histopathology in Swiss mice. Life Sci. 2013; 93:882-888
183. Delgado J, Terron M, Garcia-Martinez V, Lopez-Sanchez C, Barriga C, Pariente JA, Rodriguez AB. Oral melatonin administration and programmed cell death of neutrophils, lymphocytes, and other cell types from rats injected with HL-60 cells. J Appl Biomed. 2011; 9:197-207
184. Casado-Zapico S, Martin V, Garcia-Santos G, Rodriguez-Blanco J, Sanchez-Sanchez AM, Luno E, Suarez C, Garcia-Pedrero JM, Menendez ST, Antolin I, Rodriguez C. Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients. J Pineal Res. 2011; 50:345-355
185. Sanchez-Sanchez AM, Martin V, Garcia-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Suarez-Garnacho S, Antolin I, Rodriguez C. Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells. Free Radical Res. 2011; 45:1333-1341
186. Martín V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolín I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013; 108:2005-2012
187. Casado-Zapico S, Rodriguez-Blanco J, Garcia-Santos G, Martin V, Sanchez-Sanchez AM, Antolin I, Rodriguez C. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: Potentiation of the extrinsic apoptotic pathway. J Pineal Res. 2010; 48:72-80
188. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F, Tancini G. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology. 1995; 52:243-245
189. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995; 71:854-6
190. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999; 35:1688-1692
191. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res. 2003; 35:12-15
192. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003; 23:1951-1954
193. Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, Wang C, Kiss A, Pritchard KI, Bjarnason GA. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016; 24:1097-1105
194. Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gogenur I. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: A randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2014; 145:683-695
195. Madsen MT, Hansen MV, Andersen LT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gogenur I. Effect of melatonin on sleep in the perioperative period after breast cancer surgery: A randomized, double-blind, placebocontrolled trial. J Clin Sleep Med. 2016; 12:225-233
196. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES. A randomized, placebocontrolled trial of melatonin on breast cancer survivors: Impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014; 145:381-388
197. Di Bella G, Mascia F, Ricchi A, Colori B. Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: A preliminary report. Neuroendocrinol Lett. 2013; 34:660-668
198. Schernhammer ES, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Chen WY. A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes Control. 2012; 23:609-616
199. Rasmussen CL, Olsen MK, Johnsen AT, Petersen MA, Lindholm H, Andersen L, Villadsen B, Groenvold M, Pedersen L. Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. Cancer. 2015; 121:3727-3736